This is the authors' abstract. We don't add key points for this paper.
Hepatocellular carcinoma (HCC) ranks as the sixth most common malignancy and the third leading cause of cancer-related death globally, with approximately 900 000 new cases and 830 000 deaths reported in 2020 [1]. Recent data highlight a rising trend in mortality from viral hepatitis, with 83% of these deaths attributed to hepatitis B virus (HBV) infection. Despite this, at the end of 2022, only 13% of individuals living with chronic hepatitis B (CHB) had been diagnosed and a mere 3% had received antiviral therapy [2]. Achieving universal access to prevention, timely diagnosis and effective treatment will be essential to meet the World Health Organization (WHO) targets of eliminating viral hepatitis and reducing new hepatitis infections by 90% and deaths by 65% by 2030. Identifying antiviral therapies that effectively reduce HCC risk is crucial. The long-term efficacy of nucleos(t)ide analogues (NUCs) as antiviral therapy for CHB patients has been well established [3, 4]. In particular, numerous studies have shown that long-term NUC treatment significantly reduces the risk of HCC compared to no treatment [5, 6]. However, HCC sometimes develops despite NUC treatment. The risk factors for developing HCC include viral factors (such as viral load), host viral factors (such as older age, male sex and cirrhosis) and environmental factors [7, 8], but the association of environmental factors with HCC remains to be elucidated. In this issue of Liver International, Jang et al. [9] enrolled 1298 CHB patients undergoing NUC treatment in Taiwan to evaluate the association between air pollution and HCC incidence during the treatment period (median follow-up: 33 months). Individual exposure to air pollutants was assessed using data for four key measurements: particulate matter ≤ 2.5 μm in diameter (PM2.5), particulate matter ≤ 10 μm in diameter (PM10), nitrogen dioxide (NO2) and ozone (O3): collected from Taiwan Air Quality Monitoring (TAQM) stations. The township-level average concentrations of these pollutants were calculated based on each patient's residential address. The results revealed a significant association between air pollutant levels and the development of HCC by patients with cirrhosis, while no such association was observed for non-cirrhotic patients. In particular, NO2 levels emerged as an independent risk factor for HCC incidence in multivariable Cox regression analysis, alongside male sex. In general, air pollution is a significant contributor to the global burden of disease, leading to increased mortality, morbidity and reduced life expectancy [10]. Air pollution-related carcinogenesis is likely to follow a multistep process: initiation, promotion and progression [11]. Long-term exposure to PM2.5 and NO2 has been clearly associated with the incidence of lung cancer [12], cardiovascular diseases [13] and chronic obstructive pulmonary disease [14]. A study conducted in the United States demonstrated a significant rise in respiratory mortality associated with increased O3 concentrations [15]. Fine particulate matter can penetrate deeply into the lungs, reaching the alveoli where oxygen exchange occurs. Major sources of this type of pollutant are soot emitted directly by combustion sources and particles formed in the atmosphere from gaseous precursors such as NO2. The global population-weighted mean annual PM2.5 concentration was 46 μg/m3 in 2017 [16], comparable to the PM2.5 concentration (40.0 μg/m3) reported in the current study from Taiwan [9]. This level is four times higher than the WHO's recommended guideline of 10 μg/m3. High-income areas of the Asia Pacific recorded the highest population-weighted mean NO2 concentrations (4.9 ppb) between 1996 and 2012 [16]. While epidemiological evidence linking air pollution to cancers other than lung cancer is limited, a growing number of studies suggest a potential association between air pollution and other malignancies [16, 17]. However, too few studies focus on these malignancies, and the results are often inconsistent. Furthermore, the strong correlation between many cancers and cigarette smoking or second-hand smoke complicates the interpretation of air pollution's role in cancer development. Although the pathophysiological mechanisms linking air pollution exposure to liver diseases remain largely unexplored, several epidemiological studies have suggested potential connections. For instance, long-term exposure to air pollution, particularly PM2.5, was strongly associated with increased risks of non-alcoholic fatty liver disease and cirrhosis, possibly due to chronic inflammation, oxidative stress and insulin resistance [18]. The Jang group previously reported that higher O3 levels—but not PM2.5 or NO2—were significantly associated with persistent alanine aminotransferase abnormalities in CHB patients undergoing NUC treatment [19]. In contrast, the current study found that higher NO2 levels were linked to HCC incidence in cirrhotic patients treated with NUC, while O3 was not a significant factor [9]. Although the findings from both studies appear inconsistent, with high baseline levels of PM2.5, NO2 and O3 observed across all patient groups, they nonetheless indicate that air pollution plays a role in liver disease progression and the development of HCC. Additionally, data on the tobacco smoking habits of patients, one of the major sources of indoor air pollution, should be included to better assess the relation of particulate matter to the development of HCC. The findings reported by Jang et al. provide significant evidence supporting a strong association between air pollution and the development of HCC by patients with CHB, particularly those with cirrhosis, despite NUC treatment. Among various air pollution factors, NO2 levels emerged as the most influential in multivariable analysis. Mortality related to long-term air pollution exposure has been notably high in Asian countries [10], an area in which HBV infection is highly prevalent. Consequently, continued implementation of aggressive air quality management programmes through policy interventions will be essential for improving life expectancy in these populations. Eiichi Ogawa received research grants from Gilead Sciences. The other author declares that he has no conflict of interest. Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ogawa et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: